logo
Kerala's Beloved 'Two Rupee Doctor' Passes Away After A Lifetime Of Healing

Kerala's Beloved 'Two Rupee Doctor' Passes Away After A Lifetime Of Healing

News1819 hours ago
Dr Rairu died in the early hours of Sunday at the age of 80, leaving behind a legacy of compassionate and selfless medical care that healed countless patients.
Nearly six decades ago, Dr A Gopalan Nambiar, a respected doctor in Kannur, northern Kerala, advised his son Rairu at the beginning of his medical career, 'If it's about making money, do some other job." This piece of advice profoundly influenced the life of the young doctor. Consequently, Dr AK Rairu Gopal began his practice by charging just Rs 2 as a consultation fee, a rate he maintained for over half a century, earning him the nickname 'Two Rupee Doctor." Dr Rairu died in the early hours of Sunday at the age of 80, leaving behind a legacy of compassionate and selfless medical care that healed countless patients, especially the deprived and underprivileged.
Chief Minister Pinarayi Vijayan, who referred to Dr Rairu as 'the people's doctor," expressed condolences, noting that his dedication to service was a great relief to the poor.
Dr Rairu completed his MBBS from Kozhikode Medical College and initially worked at a hospital in Kannur before opening his own clinic in Talap, where he served the community for 35 years. He later moved to a house near Thana Manikkakavu Temple. Locals noted that bus services added a stop at Dr Rairu's clinic near the police ground in Kannur town to facilitate patients.
Dr Rairu used to examine patients from 4 am to 4 pm. Recognising the time constraints faced by workers, he began seeing patients as early as 3 am, sometimes attending to over 300 people in a day. On most days, he would see more than 200 patients. According to his own account, nearly 18 lakh patients, ranging from children to the elderly, sought his care over his career.
He primarily prescribed low-cost, effective medicines and often provided them free of charge to those in financial need. Patients came from outside the district due to his nominal fee of Rs. 2, which he later increased to Rs. 10.
Dr Rairu's daily routine was marked by discipline and simplicity. He woke up at 2:15 am, first tending to his cows, cleaning the shed, and collecting milk. After prayer and distributing milk, he would begin consultations. His journey into voluntary service began after witnessing the dire condition of a patient during a house visit.
His wife, Dr Shakuntala, supported him in managing the crowd and distributing medicines. Together with his brothers, Dr Venugopal and Dr Rajagopal, he continued the family tradition of non-profit medical service.
Dr Rairu is also survived by his son Bala Gopal and daughter Vidhya Bharath. He was honoured with the Indian Medical Association (IMA) award for the best family doctor in Kerala. Beyond his profession, Dr Rairu was a passionate animal lover who kept several pets. His body was cremated at Payyambalam, Kannur, on Sunday afternoon.
view comments
First Published:
August 05, 2025, 12:17 IST
Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Indian generics wave next year set to sink obesity drug price
Indian generics wave next year set to sink obesity drug price

Time of India

time2 hours ago

  • Time of India

Indian generics wave next year set to sink obesity drug price

As several leading Indian drugmakers are readying to launch the generic versions of Danish drug maker Novo Nordisk 's blockbuster weight-loss drug semaglutide in March next year, its price is expected to crash by as much as 80% from the prevailing rate, analysts told ET. Branded Wegovy , Novo Nordisk's drug is set to lose its patent exclusivity in March in India, triggering a rush of generic copies and making it widely available and affordable. Drugmakers such as Dr Reddy's, Sun Pharmaceutical Industries , Cipla , Mankind Pharma , Torrent Pharmaceuticals , Zydus Lifesciences and Eris Lifesciences are gearing up to enter the market with affordable versions, said senior company executives. This will make adoption among the obese and diabetes patients easier and help reduce the cost of the drug by more than 90% within three-four years from about Rs 17,000-26,000 a month at present, depending on the dosage strength, as per analysts. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Join new Free to Play WWII MMO War Thunder War Thunder Play Now Undo The domestic weight-loss drug market is expected to expand to Rs 8,000-10,000 crore by the turn of the decade from about Rs 700 crore at present. 'Weight-loss molecules like semaglutide and tirzepatide will be the largest category of drugs in the country in the next 4-5 years,' said Vishal Manchanda, pharma analyst at Systematix Group. 'While semaglutide going off patent will trigger immediate price erosion of 80%, it will also lead to a significant spike in adoption of this class of drugs.' The market size in the first 12- 24 months after the expiry of semaglutide patent in India is estimated to be Rs 4,000- 6,000 crore, before nearly doubling thereafter by 2030, he said. There are about 254 million classified as obese in India and about 40 million are on diabetes medications . 'Looking at the trend in developed markets like the US, the number of Indians taking weight-loss or GLP-1 (glucagon-like peptide-1) drugs is pegged at about 1.2 million in the first two years and 4 million by 2029-2030,' said Manchanda. Live Events Currently, about 100,000 people in the country are estimated to be on GLP-1 drugs. Till June, sales of rival Eli Lilly's Mounjaro stood at Rs 50 crore since its launch in March, while Wegovy recorded Rs 2.53 crore within a week of launch. 'Sales volumes of the drug will expand 3-4x in the first year and about 10x in five years,' said Bino Pathiparampil, head of research at Elara Capital. He estimates the Indian market to expand to $1 billion (about Rs 8,800 crore) in the next three to five years. Wegovy is currently priced at Rs 17,345 to Rs 26,050 per pen-filled injection, which comprises a month's dose of four once-a-week shots. It is available in five dosage strengths (0.25, 0.5, 1, 1.7 and 2.4 mg). Mounjaro (tirzepatide) comes in 2.5 mg and 5 mg vials, which are also given on a weekly basis, and is priced at Rs 14,000 to Rs 17,500 for a month's dose. Vyankatesh Shivane, diabetology and endocrinology consultant at Jaslok Hospital & Research Centre in Mumbai, said Mounjaro has captured the major share of the Indian market so far due to its early launch and higher weight loss efficacy. 'Diabetes patients prefer Wegovy, while non-diabetes obese patients prefer Mounjaro,' he said. Mounjaro has a weight loss efficacy of 20-22% while Wegovy has a weight loss efficacy of 16-18%. 'The world will move towards twincretins like tirzepatide because they have higher weight loss efficacy,' Shivane said. Twincretins are dual agonists of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors that are involved in regulating blood sugar levels and appetite. Novo Nordisk is looking at developing a combination of semaglutide and cagrilintide that could potentially have a 20% higher weight loss efficacy.

Day after relief for AAP's Satyendar Jain in PWD hiring case, Delhi govt claims Rs 650-cr fraud in LNJP project
Day after relief for AAP's Satyendar Jain in PWD hiring case, Delhi govt claims Rs 650-cr fraud in LNJP project

Indian Express

time2 hours ago

  • Indian Express

Day after relief for AAP's Satyendar Jain in PWD hiring case, Delhi govt claims Rs 650-cr fraud in LNJP project

A day after a CBI closure report in a corruption case came as a relief to former Delhi minister Satyendar Jain, the BJP government on Tuesday levelled fresh allegations of irregularities in the construction of a new block at the LNJP Hospital under the previous Aam Aadmi Party (AAP) government. Public Works Department (PWD) Minister Parvesh Sahib Singh said the government has sent a file to Lt Governor V.K. Saxena for a probe into the matter. The AAP, however, rejected the claims and slammed the ruling BJP over 'frivolous and baseless cases' in a statement. Speaking to the reporters, the PWD Minister claimed that the project's budget was inflated by Rs 650 crore during Jain's tenure as the PWD and health minister. 'There is a difference between the budget sanctioned for the construction of a new block at LNJP Hospital earlier and today. The amount has increased by Rs 650 crore. Jain suggested changes during reviews to benefit the contractors, which led to cost escalation. There was a scam of Rs 650 crore. We have sent a file to the L-G on this matter. He will forward it to either ACB Or CBI for inquiry in the matter,' Singh said. According to officials, a committee was constituted to examine the procedural lapses, which found that the original contract amount was Rs 465 crore, which escalated to Rs 1,139 crore, almost 243% higher. The committee highlighted irregularities and violations in consultancy work under Jain. It also alleged the 'selection of the favoured architect consultant was done through a questionable process that was marred with irregularities and in gross violation of provisions of GFR'. According to documents, the consultancy work was awarded for an area of 84,420 sqm with a value of Rs 5.27 crore to a contractor on nomination basis without calling for any tender as per the decision of the then Health Minister. It also stated that even as six consultants were empanelled, it was specifically noted that financial bids were called separately for each project. 'However this condition was flouted and then arbitrary decision was taken to appoint consultants district wise or region wise, stating that a single consultant with deal with all projects there in… Bids were invited for consultancy work pertaining to district central for an area of 90,000 square metres with the value of Rs. 5.62 crore,' reads the document. Meanwhile, AAP in its response said, 'The BJP and its ministers are obsessed with the ACB, CBI, and ED. Every day, they hatch conspiracies against AAP leaders, waste time drafting baseless and frivolous cases, and squander taxpayers' money on directionless investigations.' On the PWD hiring case, it added, 'Just a day ago, the court taught them a lesson by closing one of the CBI cases against Satyendar Jain. The court clearly stated that the CBI had registered a baseless case with no corruption, no criminality, and no evidence. Yet, the minister's home was raided, and he was harassed for eight years.'

Ayushman Bharat scheme: Haryana releases budget, initiates hospital payments
Ayushman Bharat scheme: Haryana releases budget, initiates hospital payments

Time of India

time3 hours ago

  • Time of India

Ayushman Bharat scheme: Haryana releases budget, initiates hospital payments

1 2 Chandigarh: The state health agency, Haryana, on Tuesday urged all the stakeholders to mellow down their call of withdrawal of services under the Ayushman scheme as a protest. In an official communication to the stakeholders, the health agency stated that the budget was received from the state govt on August 4, and accordingly, payment to empanelled hospitals was initiated on a first-in-first-out basis. The development reflects the state govt's commitment to ensuring timely disbursement of funds and uninterrupted delivery of healthcare services under the Ayushman Bharat scheme, read the communication. The state health agency (SHA), Haryana, has already processed and paid claims submitted by the empanelled hospitals up to the first week of May 2025. A total of Rs 2,900 crore was disbursed to hospitals since the inception of the scheme. During the financial year 2025-26, up to July 16, an amount of Rs 240.63 crore was received from the state and central govts and fully utilised for the settlement of eligible claims, stated the SHA. Claims submitted by empanelled hospitals are processed by a team of 50 doctors through the NHA's online platform. The portal ensures a transparent and impartial claim allocation process by randomly assigning cases to processors. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like With temperatures hitting 95°F, this is the mini air conditioner everyone's buying in the U.S News of the Discovery Undo All deductions are made strictly as per the NHA guidelines and only when adequate clinical justification or documentation is lacking. Before any rejection or deduction, hospitals are given an opportunity to upload the required supporting documents such as vital charts, clinical images, OT notes, and test reports. If a hospital disagrees with a deduction, it may file an appeal through the portal. These appeals are reviewed by a designated medical audit committee, the SHA mentioned. The state health agency has also taken cognisance of the grievances raised by hospitals regarding payment delays, claim rejections, and non-processing of claims. To date, over 400 grievances from empanelled hospitals have been formally registered and resolved through the Central Grievance Redressal Management System (CGRMS) 2.0 portal, it mentioned. In an effort to support hospitals in using this platform effectively, the SHA has conducted training sessions for hospital representatives. Additional training sessions are scheduled in the coming days to enhance understanding and address any functional issues. Regarding hospital empanelment and NABH incentives, all hospitals that submitted NABH incentive applications and received approval through the earlier Hospital Empanelment Module (HEM) 1.0 portal shall continue to be eligible for the incentive, provided their NABH certificates remain valid, the agency stated. Hospitals applying afresh for the NABH incentives are required to submit updated documents via the HEM 2.0 portal. Such applications are reviewed on priority by the office of the Ayushman Bharat Haryana Health Protection Authority, SHA, Haryana.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store